MedPath

Healing of Intrabony Defects Following Treatment With PRF or EMD

Not Applicable
Completed
Conditions
Periodontal Bone Loss
Periodontal Disease
Platelet Rich Fibrin
Registration Number
NCT07183631
Lead Sponsor
Semmelweis University
Brief Summary

Objective: To evaluate clinically the long-term results following treatment of deep intrabony defects with either platelet-rich fibrin gel (PRF) or an enamel matrix derivative (EMD).

Methods: Twenty six patients diagnosed with advanced chronic periodontitis, and each of whom displaying one deep intrabony defect were randomly treated with open flap debridement and with either PRF (test) or EMD (Emdogain, Straumann, Basel, Switzerland) (control). The clinical outcomes were evaluated at baseline, at six months and three years after treatment. The primary outcome variable was the clinical attachment level (CAL).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  1. No systemic conditions affecting treatment outcomes
  2. Good oral hygiene [plaque index (PI) <1; Löe 1967]
  3. Compliance with the maintenance program
  4. Presence of at least one intra-bony defect with a probing depth (PD) of ≥6 mm and an intra-bony component of ≥3 mm confirmed by radiographs.
Exclusion Criteria
  • significant medical conditions: irradiation in the maxillofacial area, uncontrolled diabetes or hypertension, systemic steroid or bisphosphonate treatment, pregnancy, or lactation, infectious diseases,
  • age <18 years, (3) smokers (>5 cigarettes/day),
  • high residual inflammation (FMBS >25%),
  • poor oral hygiene (FMPS >25%), and
  • defect-related factors: furcation involvement, endo-perio defects, horizontal defects, or multi-tooth defects .

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Probing pocket depth (PPD)preop and after 6 months
Secondary Outcome Measures
NameTimeMethod
Gingival recessionpreop and after 6 months
Clinical attachment losspreop and after 6 months

Trial Locations

Locations (1)

Semmelweis University

🇭🇺

Budapest, Hungary

Semmelweis University
🇭🇺Budapest, Hungary

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.